1
|
Gauthier C, Tavernier G, Charpentier F,
Langin D and Le Marec H: Functional β3-adrenoceptor in the human
heart. J Clin Invest. 98:556–562. 1996.PubMed/NCBI View Article : Google Scholar
|
2
|
Khullar V, Amarenco G, Angulo JC,
Cambronero J, Høye K, Milsom I, Radziszewski P, Rechberger T,
Boerrigter P, Drogendijk T, et al: Efficacy and tolerability of
mirabegron, a β3-adrenoceptor agonist, in patients with overactive
bladder: Results from a randomised European-Australian phase 3
trial. Eur Urol. 63:283–295. 2013.PubMed/NCBI View Article : Google Scholar
|
3
|
Wagg A, Cardozo L, Nitti VW, Castro-Diaz
D, Auerbach S, Blauwet MB and Siddiqui E: The efficacy and
tolerability of the β3-adrenoceptor agonist mirabegron for the
treatment of symptoms of overactive bladder in older patients. Age
Ageing. 43:666–675. 2014.PubMed/NCBI View Article : Google Scholar
|
4
|
Wagg A, Staskin D, Engel E, Herschorn S,
Kristy RM and Schermer CR: Efficacy, safety, and tolerability of
mirabegron in patients aged ≥ 65yr with overactive bladder wet: A
phase IV, double-blind, randomised, placebo-controlled study
(PILLAR). Eur Urol. 77:211–220. 2020.PubMed/NCBI View Article : Google Scholar
|
5
|
Gauthier C, Leblais V, Kobzik L, Trochu
JN, Khandoudi N, Bril A, Balligand JL and Marec HL: The negative
inotropic effect of beta3-adrenoceptor stimulation is mediated by
activation of a nitric oxide synthase pathway in human ventricle. J
Clin Invest. 102:1377–1384. 1998.PubMed/NCBI View Article : Google Scholar
|
6
|
Moniotte S, Kobzik L, Feron O, Trochu JN,
Gauthier C and Balligand JL: Upregulation of beta3-adrenoceptors
and altered contractile response to inotropic amines in human
failing myocardium. Circulation. 103:1649–1655. 2001.PubMed/NCBI View Article : Google Scholar
|
7
|
Skeberdis VA, Gendvilienė C, Zablockaitė
D, Treinys R, Macianskiene R, Bogdelis A, Jurevicius J and
Fischmeister R: β3-adrenergic receptor activation increases human
atrial tissue contractility and stimulates the L-type
Ca2+ current. J Clin Invest. 118:3219–3227.
2008.PubMed/NCBI View Article : Google Scholar
|
8
|
Nitti VW, Khullar V, Kerrebroeck P,
Herschorn S, Cambronero J, Angulo JC, Blauwet MB, Dorrepaal C,
Siddiqui E and Martin NE: Mirabegron for the treatment of
overactive bladder: A prespecified pooled efficacy analysis and
pooled safety analysis of three randomised, double-blind,
placebo-controlled, phase III studies. Int J Clin Pract.
67:619–632. 2013.PubMed/NCBI View Article : Google Scholar
|
9
|
Batista JE, Kölbl H, Herschorn S,
Rechberger T, Cambronero J, Halaska M, Coppell A, Kaper M, Huang M
and Siddiqui E: The efficacy and safety of mirabegron compared with
solifenacin in overactive bladder patients dissatisfied with
previous antimuscarinic treatment due to lack of efficacy: results
of a noninferiority, randomized, phase IIIb trial. Ther Adv Urol.
7:167–179. 2015.PubMed/NCBI View Article : Google Scholar
|
10
|
Nitti VW, Chapple CR, Walters C, Blauwet
MB, Herschorn S, Milsom I, Auerbach S and Radziszewski P: Safety
and tolerability of the β3-adrenoceptor agonist mirabegron, for the
treatment of overactive bladder: Results of a prospective pooled
analysis of three 12-week randomised phase III trials and of a
1-year randomised phase III trial. Int J Clin Pract. 68:972–985.
2014.PubMed/NCBI View Article : Google Scholar
|
11
|
Lindemann JP, Jones LR, Hathaway DR, Henry
BG and Watanabe AM: β-Adrenergic stimulation of phospholamban
phosphorylation and Ca2+-ATPase activity in guinea pig
ventricles. J Biol Chem. 258:464–471. 1983.PubMed/NCBI
|
12
|
Takasago T, Imagawa T and Shigekawa M:
Phosphorylation of the cardiac ryanodine receptor by cAMP-dependent
protein kinase. J Biochem. 106:872–877. 1989.PubMed/NCBI View Article : Google Scholar
|
13
|
Perchenet L, Hinde AK, Patel KC, Hancox JC
and Levi AJ: Stimulation of Na+/Ca2+ exchange
by the β-adrenergic/protein kinase A pathway in guinea-pig
ventricular myocytes at 37 degrees C. Pflugers Arch. 439:822–828.
2000.PubMed/NCBI View Article : Google Scholar
|
14
|
Lou Q, Janardhan A and Efimov IR:
Remodeling of calcium handling in human heart failure. Adv Exp Med
Biol. 740:1145–1174. 2012.PubMed/NCBI View Article : Google Scholar
|
15
|
Heijman J, Voigt N, Wehrens XH and Dobrev
D: Calcium dysregulation in atrial fibrillation: the role of
CaMKII. Front Pharmacol. 5(30)2014.PubMed/NCBI View Article : Google Scholar
|
16
|
Pappone C, Rosanio S, Oreto G, Tocchi M,
Gugliotta F, Vicedomini G, Salvati A, Dicandia C, Mazzone P,
Santinelli V, et al: Circumferential radiofrequency ablation of
pulmonary vein ostia: A new anatomic approach for curing atrial
fibrillation. Circulation. 102:2619–2628. 2000.PubMed/NCBI View Article : Google Scholar
|
17
|
Roithinger FX, Steiner PR, Goseki Y,
Sparks PB and Lesh MD: Electrophysiologic effects of selective
right versus left atrial linear lesions in a canine model of
chronic atrial fibrillation. J Cardiovasc Electrophysiol.
10:1564–1574. 1999.PubMed/NCBI View Article : Google Scholar
|
18
|
Lin YK, Lai MS, Chen YC, Cheng CC, Huang
JH, Chen SA, Chen YJ and Lin CI: Hypoxia and reoxygenation modulate
the arrhythmogenic activity of the pulmonary vein and atrium. Clin
Sci. 122:121–132. 2012.PubMed/NCBI View Article : Google Scholar
|
19
|
Chan CS, Lin YK, Chen YC, Kao YH, Chen SA
and Chen YJ: Hydrogen sulphide increases pulmonary veins and atrial
arrhythmogenesis with activation of protein kinase C. J Cell Mol
Med. 22:3503–3513. 2018.PubMed/NCBI View Article : Google Scholar
|
20
|
Chan CS, Lin YS, Lin YK, Chen YC, Kao YH,
Hsu CC, Chen SA and Chen YJ: Atrial arrhythmogenesis in a rabbit
model of chronic obstructive pulmonary disease. Transl Res.
223:25–39. 2020.PubMed/NCBI View Article : Google Scholar
|
21
|
National Research Council (US) Committee
for the Update of the Guide for the Care and Use of Laboratory
Animals: Guide for the care and use of laboratory animals. 8th
edition. National Academies Press (US), Washington, DC, 2011.
|
22
|
Chan CS, Chen YC, Chang SL, Lin YK, Kao
YH, Chen SA and Chen YJ: Heart failure differentially modulates the
effects of ivabradine on the electrical activity of the sinoatrial
node and pulmonary veins. J Card Fail. 24:763–772. 2018.PubMed/NCBI View Article : Google Scholar
|
23
|
Calvo-Guirado JL, Satorres M, Negri B,
Ramirez-Fernandez P, Maté-Sánchez JE, Delgado-Ruiz R, Gomez-Moreno
G, Abboud M and Romanos GE: Biomechanical and histological
evaluation of four different titanium implant surface
modifications: An experimental study in the rabbit tibia. Clin Oral
Invest. 18:1495–1505. 2014.PubMed/NCBI View Article : Google Scholar
|
24
|
Chen YJ, Chen YC, Wongcharoen W, Lin CI
and Chen SA: Effect of K201, a novel antiarrhythmic drug on calcium
handling and arrhythmogenic activity of pulmonary vein
cardiomyocytes. Br J Pharmacol. 153:915–925. 2008.PubMed/NCBI View Article : Google Scholar
|
25
|
Lu YY, Chung FB, Chen YC, Tsai CF, Kao YH,
Chao TF, Huang JH, Chen SA and Chen YJ: Distinctive
electrophysiological characteristics of right ventricular outflow
tract cardiomyocytes. J Cell Mol Med. 18:1540–1548. 2014.PubMed/NCBI View Article : Google Scholar
|
26
|
Huang SY, Lu YY, Lin YK, Chen YC, Chen YA,
Chung CC, Lin WS, Chen SA and Chen YJ: Ceramide modulates
electrophysiological characteristics and oxidative stress of
pulmonary vein cardiomyocytes. Eur J Clin Invest.
52(e13690)2022.PubMed/NCBI View Article : Google Scholar
|
27
|
McDonald TF, Pelzer S, Trautwein W and
Pelzer DJ: Regulation and modulation of calcium channels in
cardiac, skeletal, and smooth muscle cells. Physiol Rev.
74:365–507. 1994.PubMed/NCBI View Article : Google Scholar
|
28
|
Landstrom AP, Dobrev D and Wehrens XHT:
Calcium signaling and cardiac arrhythmias. Circ Res. 120:1969–1993.
2017.PubMed/NCBI View Article : Google Scholar
|
29
|
Li D, Zhang L, Kneller J and Nattel S:
Potential ionic mechanism for repolarization differences between
canine right and left atrium. Circ Res. 88:1168–1175.
2001.PubMed/NCBI View Article : Google Scholar
|
30
|
Grand AO: Cardiac ion channels. Circ
Arrhythm Electrophysiol. 2:185–194. 2009.PubMed/NCBI View Article : Google Scholar
|